Evidence map›Paper›PMID 42091109›Full record

ReviewNano letters2026

Engineering the Iron Center: Hemin Nanozymes for Programmable Cancer Catalysis.

Amir M Alsharabasy, Godspower T Isaac, Abhay Pandit

Abstract readReview
In one paragraph

Review in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amir M AlsharabasyCÚRAM, Research Ireland Centre for Medical Devices, University of Galway, Galway H91 W2TY, Ireland.ORCID 0000-0002-8503-5549
Godspower T IsaacCÚRAM, Research Ireland Centre for Medical Devices, University of Galway, Galway H91 W2TY, Ireland.ORCID 0000-0002-6990-285X
Abhay PanditCÚRAM, Research Ireland Centre for Medical Devices, University of Galway, Galway H91 W2TY, Ireland.ORCID 0000-0002-6292-4933

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment (TME) presents coupled barriers, including hypoxia, acidity, elevated hydrogen peroxide levels, and high glutathione levels, which limit the efficacy of conventional cancer therapies. Hemin, an iron protoporphyrin cofactor of hemoglobin, has emerged as a versatile catalytic node for engineered nanozymes, enabling programmable redox modulation within the TME. Through rational nanoengineering, hemin-based architectures integrate chemodynamic, photodynamic, ferroptotic, and metabolic pathways to amplify reactive oxygen species, recycle oxygen, deplete antioxidant defense, and induce iron-dependent cell death. This Review examines the developments in hemin nanotechnology, with an emphasis on precision assembly, material engineering, cascade nanoreactors, and biological modulation. We have distilled these developments into a rational design toolbox that guides scaffold selection, coordination tuning, spatial programming, and translational optimization, establishing principles for next-generation tumor-adaptive redox nanomaterials.

Indexed as

HeminIronNanostructuresNeoplasmsAnimalsCatalysisHumansNanotechnologyOxidation-ReductionReactive Oxygen SpeciesTumor MicroenvironmentHeminIronReactive Oxygen Speciescascade nanoreactorschemodynamic therapyhemin nanozymesredox modulationtumor microenvironment

Identifiers

PMID42091109
PMCPMC13195744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.